These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26107755)

  • 1. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children.
    Devlin AM; Panagiotopoulos C
    Pharmacogenomics; 2015; 16(9):981-96. PubMed ID: 26107755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related weight gain and metabolic complications in children with mental health disorders: potential role for lifestyle interventions.
    Wiedeman AM; Panagiotopoulos C; Devlin AM
    Appl Physiol Nutr Metab; 2021 Mar; 46(3):193-204. PubMed ID: 33226841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description.
    Pina-Camacho L; Díaz-Caneja CM; Saiz PA; Bobes J; Corripio I; Grasa E; Rodriguez-Jimenez R; Fernández M; Sanjuán J; García-López A; Tapia-Casellas C; Álvarez-Blázquez M; Fraguas D; Mitjans M; Arias B; Arango C
    Rev Psiquiatr Salud Ment; 2014; 7(4):166-78. PubMed ID: 25440735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients.
    Roy G; Bedard A; Desmarais PA; Jourdain F; Allen S; Michaud D; Ben Amor L
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):479-87. PubMed ID: 21186966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies for predicting side effects from second generation antipsychotics in youth.
    Brown JT; Campo-Soria C; Bishop JR
    Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):655-664. PubMed ID: 33896324
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.
    Rojo LE; Gaspar PA; Silva H; Risco L; Arena P; Cubillos-Robles K; Jara B
    Pharmacol Res; 2015 Nov; 101():74-85. PubMed ID: 26218604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic side effects of atypical antipsychotics in children: a literature review.
    Fedorowicz VJ; Fombonne E
    J Psychopharmacol; 2005 Sep; 19(5):533-50. PubMed ID: 16166191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics.
    Skonieczna-Żydecka K; Łoniewski I; Stachowska E; Marlicz W; Correll CU
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):491-495. PubMed ID: 32239144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label second generation antipsychotics for impulse regulation disorders: a review.
    Scheltema Beduin A; de Haan L
    Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The metabolic syndrome and antipsychotics in children and adolescents].
    Dori N; Green T
    Harefuah; 2011 Oct; 150(10):791-6, 814, 813. PubMed ID: 22111125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation antipsychotic medications in children and adolescents.
    Cheng-Shannon J; McGough JJ; Pataki C; McCracken JT
    J Child Adolesc Psychopharmacol; 2004; 14(3):372-94. PubMed ID: 15650494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
    Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
    J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder.
    Doane MJ; Bessonova L; Friedler HS; Mortimer KM; Cheng H; Brecht T; O'Sullivan AK; Cummings H; McDonnell D; Meyer JM
    BMC Psychiatry; 2022 Feb; 22(1):114. PubMed ID: 35164737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.
    Henderson DC
    J Clin Psychiatry; 2008 Feb; 69(2):e04. PubMed ID: 18363448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.
    DeBattista C; DeBattista K
    Curr Drug Saf; 2010 Jul; 5(3):263-6. PubMed ID: 20394571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
    Buckley PF; Miller DD; Singer B; Arena J; Stirewalt EM
    Schizophr Res; 2005 Nov; 79(2-3):281-8. PubMed ID: 15964743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia.
    Atti AR; Ferrari Gozzi B; Zuliani G; Bernabei V; Scudellari P; Berardi D; De Ronchi D; Tarricone I; Menchetti M
    Int Psychogeriatr; 2014 Jan; 26(1):19-37. PubMed ID: 24103643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.